Loading…
← CockpitCompetitor Analysis › VIR Vir Biotechnology, Inc.Open in the cockpit ↗

Vir Biotechnology, Inc.VIRCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops antibody and immune-based therapies for infectious diseases and cancer.

Momentum neutral 49
Mkt cap
$1.57B
US dollars, full cap
Free float
79%
of shares outstanding
$/day
$33.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-45.0 pp
WACC 13.1%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$9.15
1D-1.1%
1W-30.3%
1M-14.8%
3M-0.7%
6M+3.0%
YTD+51.7%
1Y+66.7%
ATR %9.1%
Beta1.82
52w lowhigh36.4% off high

What Vir Biotechnology does

Develops antibody and immune-based therapies for infectious diseases and cancer.

Has no approved product on sale, so it is funded by cash built up while its COVID antibody sold, plus occasional partner or grant income. Spending goes on trials, which means results hinge on study readouts rather than sales.

Products and services

  • Hepatitis delta/B pipeline
  • Oncology T-cell engager pipeline
  • HIV functional cure pipeline

Customers

  • Infectious disease specialists/hepatologists (post

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Infectious disease and oncology…

What could go right

  • Hepatitis delta unmet need and pivotal data
  • Pipeline diversification into oncology

What could go wrong

  • Clinical trial failure risk
  • History of pipeline discontinuations

Moat: none (IP / patents). Broad antibody engineering platform but past reliance on a discontinued COVID antibody; no current approved product.

Headquarters: San Francisco, California, US · Founded: 2016 · Employees: 367

Named competitors

Vir Biotechnology at a glance

Size Vir Biotechnology (VIR) is a United States Health Care company (Biotechnology) with a market value of $1.57B, the 1946th largest of 3,085 United States companies the cockpit tracks. Shares closed at $9.15 on 18 Nov 2026.

Performance Over six months the shares gained 3.0%, against -12.8% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue grew 1,696.0% over the last twelve months (peer median +23.4%); the operating margin is -70.2% (peer median 3.4%).

Valuation It trades at 4.0× enterprise value to sales against a peer median of 6.4× (6th cheapest of 18).

Capital Return on invested capital runs 45.0 points below its cost of capital (13.1% WACC).

Short interest Short interest is 9.8% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026VIR 101Peer median 86
Six months, rebased to 100: Vir Biotechnology against the median of its 20 peers (local-currency closes).

Vir Biotechnology financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$303M$68.6M$74.2M$86.2M$1.62B
Revenue growth—-8%-14%-95%—
Gross profit$291M$56.9M$58.8M$64.0M$1.45B
EBITDA-$201M-$456M-$509M-$642M$849M
Net income-$185M-$438M-$522M-$615M$516M
Free cash flow-$142M-$397M-$454M-$800M$1.60B
Capital expenditure$804,000$4.83M$7.30M$21.6M$68.0M
Total debt$90.8M$97.9M$97.9M$125M$128M

Quarterly statements and history in the cockpit →

Vir Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%NRIXPGENKLRAPPGN6949KRSA688222ALVOANIP688319600226087010MSB2637URGN688765145020688105VIR6-month return →1-month return →
Up and to the right = strong over both horizons. Vir Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%0×500×1,000×1,500×NRIXPGENPPGN6949KRSA688222087010MSB688765VIRRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Vir Biotechnology is the large dot.

Vir Biotechnology competitors and peer comparison

Head to head with its named competitors (VIR vs GILD vs GSK.L vs REGN)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Vir Biotechnology VIR$1.57B+3%+1,696%-70%4.0×n/a
Gilead Sciences GILD$210B+30%+7%38%7.3×-2.4%
GSK GSK.L$97.9B-3%+4%25%2.8×-0.1%
Regeneron Pharmaceuticals REGN$97.8B+46%+19%30%5.4×-1.1%

How Vir Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Vir Biotechnology against its 20 peers (data as of 18 Nov 2026)
MeasureVIRPeer medianRank in peer set
1-month return-14.8%-9.9%9th lowest of 21
6-month return+3.0%-12.8%6th highest of 20
Distance from 52-week high-36.4%-44.5%8th highest of 21
Revenue growth (TTM)+1,696.0%+23.4%2nd highest of 19
Operating margin-70.2%3.4%5th lowest of 19
EV / Sales4.0×6.4×6th cheapest of 18
ROIC minus cost of capital-45.0 pp-5.9 pp2nd lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Vir Biotechnology VIRUnited States$1.57B+3%+1,696%-70%4.0×n/an/a
Nurix Therapeutics NRIXUnited States$1.54B-14%+739%41%0.8×n/an/a
Precigen PGENUnited States$1.53B0%+2,388%21%10.1×n/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
PolyPeptide PPGN.SWSwitzerland$1.61B+7%+22%7%3.4×n/an/a
PELL Bio-Med Technology 6949.TWTaiwan$1.62B+28%+8%-1,463%1,650.2×n/an/a
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%1,058.7×n/an/a
Hitgen 688222.SSChina$1.62B-3%+42%27%14.4×33.2%+16.8%
Alvotech ALVOUnited States$1.62B+38%-14%12%6.4×n/an/a
ANI Pharmaceuticals ANIPUnited States$1.62B-13%+26%15%1.7×-7.6%+33.5%
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%13.1×n/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Zhejiang Hengtong 600226.SSChina$1.64B-31%+71%0%4.2×n/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%359.6×n/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%12.8×n/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%n/an/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%6.3×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a
Hugel 145020.KSSouth Korea$1.69B-30%+17%38%3.6×-12.1%+15.0%
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%

Questions

Who are Vir Biotechnology's main competitors?
Named competitors: Gilead Sciences (GILD), GSK (GSK.L), Regeneron (REGN). The cockpit's measured peer set (industry) also includes Nurix Therapeutics (NRIX), Precigen (PGEN), Kailera Therapeutics (KLRA), PolyPeptide (PPGN.SW), PELL Bio-Med Technology (6949.TW), Korsana Biosciences (KRSA).
Is Vir Biotechnology expensive compared with its peers?
On ev / sales it trades at 4.0× against a peer median of 6.4×, 6th cheapest of 18 in its peer set.
How has Vir Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned +3.0% against -12.8% for the median peer; over one year +66.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.